AC-262536

AC-262536 is a Selective Androgen Receptor Modulator (SARM) that was developed by Acadia Pharmaceuticals. It is known for its potential therapeutic applications in the treatment of osteoporosis, muscle wasting diseases, and prostate cancer, among other conditions.

History

AC-262536 was first developed by Acadia Pharmaceuticals, a biopharmaceutical company that specializes in the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The compound was initially synthesized as part of the company's research into novel nonsteroidal SARMs.

Pharmacology

As a SARM, AC-262536 selectively binds to the androgen receptor, a type of nuclear receptor that is activated by binding any of the androgenic hormones, including testosterone and dihydrotestosterone. This selective binding is believed to result in fewer side effects compared to traditional anabolic steroids.

AC-262536 has been shown in animal studies to have a selective anabolic effect on muscle and bone, while having little effect on the prostate. This makes it a potential candidate for the treatment of conditions such as osteoporosis and muscle wasting diseases, where an increase in muscle and bone strength is desirable, but an increase in prostate growth is not.

Clinical Trials

As of now, AC-262536 has not been tested in human clinical trials. However, preclinical animal studies have shown promising results, indicating that the compound may have potential therapeutic applications in the future.

Potential Therapeutic Applications

The selective anabolic effects of AC-262536 make it a potential candidate for the treatment of a variety of conditions. These include:

• Osteoporosis: AC-262536's ability to increase bone density could potentially be used to treat osteoporosis, a condition characterized by weak and brittle bones.
• Muscle wasting diseases: The compound's anabolic effects on muscle could potentially be used to treat diseases characterized by muscle wasting, such as muscular dystrophy or cachexia.
• Prostate cancer: While AC-262536 has little effect on the prostate, it has been suggested that it could potentially be used in combination with other treatments for prostate cancer.

See Also

• Selective Androgen Receptor Modulator
• Androgen receptor
• Osteoporosis
• Muscle wasting diseases
• Prostate cancer

‎